Content of review 1, reviewed on September 19, 2020

Brief overview of the paper and its main findings

Demyelinating diseases represent a spectrum of disorders that impose significant burden on global economy and society. Generally, the prognosis of these diseases is poor and there is no available cure. In recent decades, research has shed some light on the biology and physiology of Schwann cells and its neuroprotective effects in the peripheral nervous system (PNS). Insults to the PNS by various infectious agents, genetic predisposition and immune-related mechanisms jeopardize Schwann cell functions and cause demyelination. To date, there are no effective and reliable biomarkers for PNS-related diseases. Here, we aim to review the following: pathogenesis of various types of peripheral demyelinating diseases such as Guillain-Barre syndrome, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Anti-Myelin Associated Glycoprotein Neuropathy, POEMS syndrome, and Charcot-Marie-Tooth disease; emerging novel biomarkers for peripheral demyelinating diseases, and Schwann cell associated markers for demyelination.

Major and minor points

This should be the main substance of your review and should bring up any weaknesses, inconsistencies, things that need to be clarified or questions you have for the authors.

Conflicts of interest

NO

Do you have any conflicts of interest here?

Source

    © 2020 the Reviewer (CC BY 4.0).

References

    Khidhir, K., Dain, Y. M., Hj, I. R. B., Srijit, D., Jaya, K. 2019. Peripheral Demyelinating Diseases: From Biology to Translational Medicine. Frontiers in Neurology.